Skip header and navigation

8 records – page 1 of 1.

Document Type
Evidence Search Report
Review Code
LAB041402-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 14; Document
Document Type
Evidence Search Report
Review Code
LAB041402-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 14; Document no.: LAB041402-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 42 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB041402 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
of Literature Review Title: At what time in the disease timeline of COVID-19 do antibodies develop? Review
Document Type
Rapid Review
Review Code
LAB041402 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
The majority of patients (>50%) appear to seroconvert between 8-14 days following the onset of symptoms.
Nearly all patients (>80%) seroconvert >15 days following the onset of symptoms.
The IgM response is detected earlier (median 12 days) than the IgG response (median 14 days).
Seroconversion appears to follow clinical recovery in most cases.
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Vanstone, J; Reeder, B; Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 15; Document no.: LAB041402 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 4 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LAB041501-01 ESR
Question Submitted
April 15, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
QUESTION: How well does the presence and level of antibodies predict the clinical course of disease
Document Type
Evidence Search Report
Review Code
LAB041501-01 ESR
Question Submitted
April 15, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Priority Level
Level 2 completed within 8 hours
Cite As
Howell-Spooner, B. How well does the presence and level of antibodies predict the clinical course of disease? 2020 Apr 15; Document no.: LAB041501-01 ESR In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 22 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB041501 RR
Question Submitted
April 15, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Laboratory
Report Review Title: How well does the presence and level of antibodies predict the clinical course
Document Type
Rapid Review
Review Code
LAB041501 RR
Question Submitted
April 15, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
Seroconversion occurs in majority of COVID-19 patients from the second week following symptomonseton.
Between 7.8 -43.6% of suspect cases and 4.7% of asymptomatic individuals with negative nucleic acid test (rt-PCR) test positive for antibodies against SARS-CoV-2.
An increase in antibody titrescorrelates with a neutralizing antibody response and positive recovery of COVID-19 patients with mild to moderate symptoms.
Although higher antibody titreand more robust antibody response are observed in severe and critically ill patients, those antibodies may not effectively clear virus and higher antibody levels may be associated with a worse clinical progress.
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Howell-Spooner, B. How well does the presence and level of antibodies predict the clinical course of disease? 2020 Apr 17; Document no.: LAB041501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LAB041401-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
QUESTION: How well does the presence and level of antibodies predict the presence or absence
Document Type
Evidence Search Report
Review Code
LAB041401-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Testing
Antibodies
Serology
Priority Level
Level 2 completed within 8 hours
Cite As
Howell-Spooner, B. How well does the presence and level of antibodies predict the presence or absence of the disease? 2020 Apr 14; Document no.: LAB041401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 20 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB041401 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Report Review Title: How well does the presence and level of antibodies predict the presence
Document Type
Rapid Review
Review Code
LAB041401 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
Moderate to strong grade evidence show the overall sensitivityrangeof IgM, IgG, and combined IgM/IgG are 48.1% to 94.1%, 64.7% to 100%, 83% to 100%, respectively.
IgM/IgG combined assay, with the posterior probability of 99.15%, has greater accuracyand sensitivity than a single IgM or IgG test.
The sensitivity of antibody tests is extremely low (~ 11.1%) in the first week following the onsetof symptoms but increasesrapidlyduring the second week.
IgG and IgM titers in patients with severe disease arehigher than those in the non-severe patients.
Antibody testsmay detect the presence of COVID-19 in asymptomatic individuals with negative rt-PCRresults.
Category
Clinical Presentation
Subject
Testing
Serology
Antibodies
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Howell-Spooner, B. How well does the presence and level of antibodies predict the presence or absence of the disease? 2020 Apr 15; Document no.: LAB041401 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 9 p. (CEST rapid review report)
Similar Reviews
PH042401 RR
EPM051201 RR
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LAB041601v2-01 ESR
Question Submitted
April 16, 2020
Date Completed
May 22, 2020
Status
5. Updated review
Research Team
Laboratory
RNA of throat swabs became negative and the viral specific antibodies were produced during recovery
Document Type
Evidence Search Report
Review Code
LAB041601v2-01 ESR
Question Submitted
April 16, 2020
Date Completed
May 22, 2020
Status
5. Updated review
Research Team
Laboratory
Category
Diagnostics
Clinical Presentation
Subject
Transmission
Antibodies
Natural History
Population
All
Cite As
Duncan, V; Howell-Spooner, B. What is the relationship between antibody development and viral shedding and infectiousness? 2020 May 22; Document no.: LAB041601v2-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 30 p. (CEST evidence search report)
Review History
LAB041601 RR: April 16, 2020
Related Documents
Documents

LAB041601v2-01 ESR

Read PDF Download PDF
Less detail
Document Type
Rapid Review
Review Code
LAB041601v2 RR
Question Submitted
April 16, 2020
Date Completed
May 19, 2020
Status
5. Updated review
Research Team
Laboratory
report) Key Findings • Patients with higher and prolonged IgM antibodies are associated with more
Document Type
Rapid Review
Review Code
LAB041601v2 RR
Question Submitted
April 16, 2020
Date Completed
May 19, 2020
Status
5. Updated review
Research Team
Laboratory
Key Findings
Patients with higher and prolonged IgM antibodies are associated with more severe illness, poor recovery, and prolonged viral shedding (some patients may shed virus for more than 30 days).
Patients who respond weakly to IgG have higher viral clearance rate than strong responders.
There were no reports with direct information regarding infectiousness of patients.
Category
Diagnostics
Clinical Presentation
Subject
Transmission
Antibodies
Natural History
Population
All
Cite As
Vanstone, J; Reeder, B; Duncan, V. What is the relationship between antibody development and viral shedding and infectiousness? 2020 May 19; Document no.: LAB041601v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Review History
LAB041601 RR: April 16, 2020
Related Documents
Documents
Less detail

8 records – page 1 of 1.